Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:AIM TSE:NIF.UN NASDAQ:SBC NYSEARCA:XLY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIMAIM ImmunoTech$2.57-0.8%$4.97$2.33▼$36.00$7.02M0.9865,209 shs29,687 shsNIF.UNNoranda Income FundC$0.00C$0.26▼C$1.99C$73.86M1.46171,754 shs9,593 shsSBCSBC Medical Group$4.73-5.2%$4.53$2.62▼$12.50$518.37M1.2749,298 shs68,169 shsXLYConsumer Discretionary Select Sector SPDR Fund$235.69-0.1%$225.86$173.10▼$240.28$23.66B1.184.70 million shs6.66 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIMAIM ImmunoTech-0.77%+6.20%+2.80%-71.88%-91.71%NIF.UNNoranda Income Fund0.00%0.00%0.00%0.00%0.00%SBCSBC Medical Group-5.21%+16.50%+7.50%+1.94%+472,999,900.00%XLYConsumer Discretionary Select Sector SPDR Fund-0.14%+2.47%+5.32%+9.77%+27.37%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIMAIM ImmunoTech$2.57-0.8%$4.97$2.33▼$36.00$7.02M0.9865,209 shs29,687 shsNIF.UNNoranda Income FundC$0.00C$0.26▼C$1.99C$73.86M1.46171,754 shs9,593 shsSBCSBC Medical Group$4.73-5.2%$4.53$2.62▼$12.50$518.37M1.2749,298 shs68,169 shsXLYConsumer Discretionary Select Sector SPDR Fund$235.69-0.1%$225.86$173.10▼$240.28$23.66B1.184.70 million shs6.66 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIMAIM ImmunoTech-0.77%+6.20%+2.80%-71.88%-91.71%NIF.UNNoranda Income Fund0.00%0.00%0.00%0.00%0.00%SBCSBC Medical Group-5.21%+16.50%+7.50%+1.94%+472,999,900.00%XLYConsumer Discretionary Select Sector SPDR Fund-0.14%+2.47%+5.32%+9.77%+27.37%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAIMAIM ImmunoTech 3.00Buy$275.0010,600.39% UpsideNIF.UNNoranda Income Fund 0.00N/AN/AN/ASBCSBC Medical Group 0.00N/AN/AN/AXLYConsumer Discretionary Select Sector SPDR Fund 2.67Moderate Buy$235.69N/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAIMAIM ImmunoTech$121K57.54N/AN/A$0.20 per share12.85NIF.UNNoranda Income FundC$887.61M0.00N/A7.50C$4.54 per share0.00SBCSBC Medical Group$205.42M2.39$0.57 per share8.23$1.90 per share2.49XLYConsumer Discretionary Select Sector SPDR FundN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAIMAIM ImmunoTech-$28.96M-$24.68N/AN/AN/A-12,594.21%-421.73%-147.54%N/ANIF.UNNoranda Income FundC$12.88MC$0.355.63N/AN/A1.45%6.26%7.05%N/ASBCSBC Medical Group$46.61M$0.3214.780.84N/A17.71%20.76%15.56%11/12/2025 (Estimated)XLYConsumer Discretionary Select Sector SPDR FundN/AN/A27.10∞N/AN/AN/AN/AN/ALatest NIF.UN, AIM, XLY, and SBC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025SBCSBC Medical Group$0.14$0.02-$0.12$0.02$44.71 million$43.36 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAIMAIM ImmunoTechN/AN/AN/AN/AN/ANIF.UNNoranda Income FundN/AN/AN/AN/AN/ASBCSBC Medical GroupN/AN/AN/AN/AN/AXLYConsumer Discretionary Select Sector SPDR Fund$1.820.77%N/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAIMAIM ImmunoTech0.050.750.75NIF.UNNoranda Income Fund108.272.140.85SBCSBC Medical Group0.033.983.95XLYConsumer Discretionary Select Sector SPDR FundN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAIMAIM ImmunoTech12.02%NIF.UNNoranda Income Fund8.18%SBCSBC Medical Group60.82%XLYConsumer Discretionary Select Sector SPDR Fund69.93%Insider OwnershipCompanyInsider OwnershipAIMAIM ImmunoTech0.02%NIF.UNNoranda Income Fund12.61%SBCSBC Medical Group89.47%XLYConsumer Discretionary Select Sector SPDR FundN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAIMAIM ImmunoTech202.71 million68.74 millionNot OptionableNIF.UNNoranda Income Fund53737.49 millionN/ANot OptionableSBCSBC Medical GroupN/A103.88 million10.94 millionN/AXLYConsumer Discretionary Select Sector SPDR Fund147,000100.40 millionN/ANot OptionableNIF.UN, AIM, XLY, and SBC HeadlinesRecent News About These CompaniesWhat August Labor Data Means for the S&P 500 in September (XLY)...September 8 at 10:12 AM | marketbeat.comReturn of the ETFs: 3 Names That Could Keep Outperforming (XLY)...September 4, 2025 | marketbeat.comTrade's Biggest Threat Isn't Tariffs—It's UncertaintySeptember 3, 2025 | msn.comWhat to Expect From the Q3 Reporting Season (XLY)...September 3, 2025 | marketbeat.comRoyal Caribbean, Deckers, MGM Shine As Consumer Stocks Extend Weekly Gains After Powell's Rate-Cut TeaseAugust 25, 2025 | msn.comXLY: Don't Expect Consumer Spending To Notably Recover Until 2026August 21, 2025 | seekingalpha.comConsumer Strength Signal Flashing Short-Term Caution SignAugust 20, 2025 | schaeffersresearch.comAre Cyclical ETFs Worth the Boom and Bust?August 18, 2025 | finance.yahoo.comLululemon, Wendy’s, Peloton Get Some Institutional Love As Hedge Funds Shuffle Consumer Stocks DeckAugust 15, 2025 | msn.com5 ETFs to Benefit if Fed Cuts Rate in SeptemberAugust 11, 2025 | zacks.comWhat Tariffs Mean for Your Sector ExposureAugust 8, 2025 | msn.comShould You Invest in the Consumer Discretionary Select Sector SPDR ETF (XLY)?August 6, 2025 | zacks.comTrump Tariff Blows Didn’t Stop These 3 Stocks From Defying Last Week’s Consumer SlumpAugust 4, 2025 | msn.comLooking for Exposure to Amazon Stock (AMZN) Post Q2 Dip? Try These Two ETFsAugust 2, 2025 | msn.comStrong Start to Q2 Earnings Season: 4 Sector ETFs to PlayJuly 30, 2025 | zacks.com4 Sector ETFs to Play on Improving Earnings TrendsJuly 28, 2025 | zacks.comEarnings Scoreboard: 12 of 17 consumer cyclical stocks beat estimates last weekJuly 27, 2025 | msn.comConsumer Durables: Overview, What They Are, ExampleJuly 25, 2025 | fool.comETFs to Consider as Consumer Sentiment Improves in JulyJuly 21, 2025 | zacks.comWeekly Economic Snapshot: Consumer Spending Rebounds Despite Rising InflationJuly 21, 2025 | etftrends.comEConsumer Stocks Post Weekly Gains As Retail Sales Rebound, Inflation Picks Up: Here Are The Top 3 WinnersJuly 21, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesHow Did Peter Thiel-Backed Crypto Exchange Bullish's IPO Go?By Jordan Chussler | August 14, 2025Alphabet Reclaims $200 Threshold—Bull Run Reignited?By Ryan Hasson | August 12, 2025Is It Too Late to Jump on the Nuclear Bandwagon? By Jordan Chussler | August 25, 2025AI Glasses to Replace Smartphones? Meta Is Taking Aim at AppleBy Leo Miller | August 16, 2025Advanced Micro Devices' 2026 Forecasts Are Way Too LowBy Thomas Hughes | September 5, 2025NIF.UN, AIM, XLY, and SBC Company DescriptionsAIM ImmunoTech NYSE:AIM$2.57 -0.02 (-0.77%) Closing price 09/9/2025 04:00 PM EasternExtended Trading$2.48 -0.09 (-3.31%) As of 06:42 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente; Jubilant HollisterStier; Sterling Pharma Solutions; Erasmus University Medical Center Rotterdam; Azenova, LLC; and Alcami Corporation. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.Noranda Income Fund TSE:NIF.UNNoranda Income Fund operates as an income trust. The company owns electrolytic zinc processing facility and ancillary assets located in Salaberry-de-Valleyfield, Québec that produces refined zinc metal and various by-products from zinc concentrate. Its products include jumbo zinc, a product customized with alloy for steel customers to enhance the productivity of galvanizing lines; zinc shot, a product that is used to produce electro-galvanized steel for the car industry; and granulated zinc that is used in the production of fertilizers and reagents for the pulp and paper industry. The company's by-products comprise copper cake, cadmium, and sulphuric acid. It serves customers in Canada, the United States, and internationally. The company was founded in 1963 and is headquartered in Toronto, Canada.SBC Medical Group NASDAQ:SBC$4.73 -0.26 (-5.21%) Closing price 09/9/2025 04:00 PM EasternExtended Trading$4.61 -0.13 (-2.64%) As of 09/9/2025 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SBC Medical Group Holdings Incorporated, through its subsidiaries, provides services to support the operation of clinics which deliver specialized medical services in the areas of cosmetic medicine, esthetic dentistry and Androgenetic Alopecia or AGA, primarily in Japan and centered on the SBC Shonan Beauty Clinic Brand. SBC Medical Group Holdings Incorporated, formerly known as Pono Capital Two Inc., is based in TOKYO.Consumer Discretionary Select Sector SPDR Fund NYSEARCA:XLY$235.69 -0.33 (-0.14%) Closing price 09/9/2025 04:10 PM EasternExtended Trading$234.97 -0.72 (-0.31%) As of 06:07 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Consumer Discretionary Select Sector SPDR Fund seeks to provide investment results that correspond generally to the price and yield performance of the Consumer Discretionary Select Sector Index (the Index). The Index includes companies from the following industries, media; retail (specialty, multiline, Internet and catalog); hotels, restaurants and leisure; textiles, apparel and luxury goods; household durables; automobiles; auto components; distributors; leisure equipment and products; and diversified consumer services. The Fund's investment advisor is SSgA Funds Management, Inc. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Is Qualcomm Tesla’s Next Rival in Autonomous Driving? Casey’s General Stores: Investors Win With CASY at the Bat Should You Buy Figma Stock After Its 55% Post-IPO Drop? Ulta Beauty Stock: Strong Growth, Short-Term Volatility Ahead Joby's Stock Is Quiet, But a Storm of Catalysts Is Brewing The Quiet Before the Catalyst: Vertical Aerospace's Next Move Novartis' Moonshot Cancer Therapy Could Be Future Growth Driver Insiders Sell These High-Quality Stocks: Why Investors Shouldn’t Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
